Andrew Daluga, MD
Emergency Medicine · Greenfield, INNPI 1790103315
Payments from drug & device makers
Across 191 payments — averaging $5985.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1.1M
- AbbVie$38K
- Alnylam Pharmaceuticals Inc.$37K
- Novartis$11K
- AstraZeneca$160
- GSK$154
- plus $503 from 10 others
Across 10 payments — averaging $239.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$2K
- Eli Lilly$570
What the payments were for
- Travel & lodging$42432%
- Food & beverage$89168%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 18 | $1,056,367 |
| AbbVie | 20 | $38,072 |
| Alnylam Pharmaceuticals Inc. | 100 | $36,584 |
| Novartis | 3 | $11,479 |
| AstraZeneca | 8 | $160 |
| GSK | 9 | $154 |
| Lilly USA, LLC | 8 | $128 |
| Exact Sciences | 4 | $81 |
| Amgen | 5 | $63 |
| Pfizer | 4 | $57 |
| Boehringer Ingelheim | 3 | $50 |
| E.r. Squibb & Sons, L.L.C. | 3 | $37 |
| Novo Nordisk | 2 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $22 |
| Astellas Pharma US Inc | 1 | $19 |
| Merck | 1 | $13 |
How this compares
$1,143,320 in reported general payments places this provider in the 95th percentile of 1,073 emergency medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 93 | $132,029 |
| MounjaroTirzepatide | 88 | $113,758 |
| EliquisApixaban | 90 | $77,738 |
| JardianceEmpagliflozin | 49 | $64,773 |
| RybelsusSemaglutide | 19 | $40,504 |
| TrulicityDulaglutide | 21 | $39,628 |
| XareltoRivaroxaban | 43 | $34,591 |
| JanuviaSitagliptin Phosphate | 33 | $25,077 |
| MyrbetriqMirabegron | 37 | $22,686 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $21,145 |
| RexultiBrexpiprazole | 12 | $19,124 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $13,168 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 59 | $13,016 |
| FarxigaDapagliflozin Propanediol | 11 | $13,002 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $12,628 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $33 | $172,533112 claims |
| Lilly USA, LLCMounjaro, Trulicity | $128 | $153,386109 claims |
| PfizerEliquis | $57 | $77,73890 claims |
| Boehringer IngelheimJardiance | $50 | $64,77349 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Anoro Ellipta | $154 | $59,956129 claims |
| MerckJanuvia | $13 | $25,07733 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $22,68637 claims |
| AstraZenecaFarxiga | $160 | $13,00211 claims |
| AbbVieSynthroid | $38,072 | $3,81644 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,073 emergency medicine providers in Indiana.
Other emergency medicine in Greenfield
- Joseph Newbergla Porte$9.9M
- Peter PangIndianapolis$1.1M
- Nicholas HarrisonIndianapolis$417K
- Jeffrey KlineIndianapolis$376K
- Benton HunterIndianapolis$125K
- Roy AbrahamPortland$80K
- Michael BrownIndianapolis$80K
- Michael MartinoBedford$67K
- Jeffrey GreenspanIndianapolis$60K
- Daren BeamIndianapolis$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.